Final results from IMPROVE: A randomized, controlled, open-label, cross-over phase IV study to determine the patients’ preference for either combined endocrine therapy (exemestane plus everolimus) or immunochemotherapy (capecitabine plus bevacizumab) as first line treatment for advanced HR+/HER2- breast cancer. 26. Dezember 2018 Kurbacher, C., Söling, U., Hahn, A., Chiabudini, M., Maintz, C., Rieger, L., Falkenstein, J., Runkel, E., Potthoff, K., Decker, T., 2019. Cancer Res 79 (4 Supplement)(P6-21–11). doi:10.1158/1538-7445.SABCS18-P6-21-11 Abstract SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). Retz, M., Bedke, J., Bögemann, M., Grimm, M.-O., Zimmermann, U., Müller, L., Leiber, C., Teber, D., Wirth, M., Bolenz, C., van Alphen, R., De Santis,… Weiterlesen Results from a prospective real world study show strong efficacy of idelalisib in CLL, including high-risk CLL, and provide evidence that PJP prophylaxis positively impacts on overall survival. Hoechstetter, M., Eissmann, P., Hucke, N., van Troostenburg, A., Ramroth, H., Knauf, W., 2018. Blood 132 (suppl 1), 4428. https://doi.org/10.1182/blood-2018-99-112843… Weiterlesen